Rivkees S A, Bode H H, Crawford J D
Pediatric Endocrine Unit of the Children's Service, Massachusetts General Hospital, Boston 02114.
N Engl J Med. 1988 Mar 10;318(10):599-602. doi: 10.1056/NEJM198803103181003.
It has been suggested that complete catch-up growth is achieved with treatment in patients with juvenile acquired hypothyroidism. We tested this assumption by examining long-term growth in 18 girls (mean [+/- SD] age, 11.4 +/- 2.7 years; bone age, 6.2 +/- 3.1 years) and 6 boys (age, 10.6 +/- 4.7 years; bone age, 6.4 +/- 2.7 years) with severe primary hypothyroidism (serum thyroxine level 1.1 +/- 0.3 micrograms per deciliter [13 +/- 4 nmol per liter]). At diagnosis, heights were 4.04 +/- 0.5 and 3.15 +/- 0.4 SD below the mean heights for age of normal girls and boys, respectively. The patients were treated with levothyroxine (3.4 +/- 0.3 micrograms per kilogram of body weight per day) to maintain normal thyroid function. During the first 18 months of therapy, the children's skeletal maturation exceeded the maturation expected for their statural growth, regardless of whether or not they were undergoing pubertal development. Predictions of decreased adult height were based on these observations. At maturity, girls and boys stood approximately 2 SD below normal adult stature, at 149 +/- 5.0 cm and 168 +/- 5.1 cm, respectively. Heights at maturity were also lower than midparental heights (P less than 0.01) and lower than pre-illness standard-deviation scores for height (P less than 0.01). The deficit in adult stature was significantly related to the duration of hypothyroidism before treatment (P less than 0.01). We conclude that despite treatment, prolonged juvenile acquired hypothyroidism results in a permanent height deficit related to the duration of thyroxine deficiency before treatment.
有人提出,青少年获得性甲状腺功能减退症患者通过治疗可实现完全追赶生长。我们通过研究18名女孩(平均[±标准差]年龄为11.4±2.7岁;骨龄为6.2±3.1岁)和6名男孩(年龄为10.6±4.7岁;骨龄为6.4±2.7岁)的长期生长情况来验证这一假设,这些患儿患有严重原发性甲状腺功能减退症(血清甲状腺素水平为1.1±0.3微克/分升[13±4纳摩尔/升])。诊断时,女孩和男孩的身高分别比正常同龄女孩和男孩的平均身高低4.04±0.5和3.15±0.4个标准差。患者接受左甲状腺素治疗(每天3.4±0.3微克/千克体重)以维持正常甲状腺功能。在治疗的前18个月,无论患儿是否处于青春期发育阶段,其骨骼成熟度均超过根据身高增长预期的成熟度。基于这些观察结果预测成年身高会降低。成年时,女孩和男孩的身高分别约比正常成年人身高低2个标准差,分别为149±5.0厘米和168±5.1厘米。成年时的身高也低于父母身高的中位数(P<0.01),且低于患病前身高的标准差评分(P<0.01)。成年身高的不足与治疗前甲状腺功能减退症的持续时间显著相关(P<0.01)。我们得出结论,尽管进行了治疗,但青少年获得性甲状腺功能减退症病程延长会导致永久性身高不足,这与治疗前甲状腺素缺乏的持续时间有关。